论文信息 - Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma. - 字舞流文

Prevention of visual field defect progression with angiotensin-converting enzyme inhibitor in eyes with normal-tension glaucoma.

K. Hirooka | F. Shiraga | T. Baba | T. Fujimura

[1] D. Mari,et al. Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin‐converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation , 2005, British journal of haematology.

[2] H. Arai,et al. Angiotensin‐Converting Enzyme Inhibitors and Incidence of Alzheimer's Disease in Japan , 2004, Journal of the American Geriatrics Society.

[3] K. Hirooka,et al. Bradykinin sensitivity in primary open-angle glaucoma and normal-tension glaucoma patients. , 2002, American journal of ophthalmology.

[4] A. Akaike,et al. Protective effect of bradykinin against glutamate neurotoxicity in cultured rat retinal neurons. , 2000, Investigative ophthalmology & visual science.

[5] D. Harrison,et al. Reversing endothelial dysfunction with ACE inhibitors. A new trend. , 1996, Circulation.

[6] H. Chase,et al. Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. , 1992, Annals of ophthalmology.

[7] C. Samson,et al. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. , 1988, American journal of ophthalmology.